SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 9th, 2024 • OptiNose, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2024, between OptiNose Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
THIRD AMENDMENT TO NOTE PURCHASE AGREEMENTNote Purchase Agreement • May 9th, 2024 • OptiNose, Inc. • Pharmaceutical preparations
This Third Amendment to the Note Purchase Agreement (defined below) (this “Amendment”), dated as of May 8, 2024 (the “Third Amendment Effective Date”), is entered into by and among OPTINOSE US, INC., a Delaware corporation (the “Issuer”), OPTINOSE, INC., a Delaware corporation (the “Parent”), the Purchasers (as defined in the Note Purchase Agreement) party to the Note Purchase Agreement as of the Third Amendment Effective Date, and BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales, as Collateral Agent.
